OVERVIEW

Indy Hematology Education, Inc.

Achieving tomorrow’s outcomes through education today.™

A full day of presentations by today's leaders in Hematology and Hematologic Malignancies.  

The Indy Hematology Review™ annually offers an essential and up-to-date educational and scientific meeting for hematology professionals. Participate in the Review to hear a summary from leading hematology researchers and educators as they discuss the most recent developments to improve patient management and care. Data from major hematology and oncology conferences of the past year, including the American Society of Hematology, American Society of Clinical Oncology and the European Hematology Association Congress will be reviewed in a fast-paced format that includes Q&A.

The Indy Hematology Review™ brings together over 300 hematologists, oncologists, radiologists, physician assistants, oncology RN's, nurse practitioners, pharmacists, medical students, and other allied health professionals to examine significant scientific updates in clinical hematologic research, learn how these updates directly affect the study and practice of hematology, and discover how new research can be translated into new patient care strategies.

Plan to attend the Indy Hematology Review™ to learn this important and critical information:

1. Review new emerging Hematology therapies for Multiple Myeloma, Waldenström’s Macroglobulin, Lymphoplasmacytic Lymphoma, and Myelofibrosis.
2. Determine which targeted therapies will be appropriate for patients diagnosed with Indolent Lymphoma, Hodgkin’s Lymphoma and Myelodysplastic syndrome.
3. Evaluate which biological therapies (beyond CHOPing) that are effective in treating patients with Acute Lymphoblastic Leukemia and other Lymphomas.
4. Discuss current treatment options for patients with Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.
5. Implement best practices for the identification and treatment of patients who are candidates for Hematopoietic Stem Cell transplantation.
6. Review updated best practices for identifying, diagnosing and treating patients with Chronic Myeloid Leukemia, Essential Thrombocytosis, Eosinophilia Mastocytosis.
7. Discuss challenging hematologic malignancy cases and assess potential solutions for optimal patient care.

LEANING OBJECTIVES

Upon completion of this activity, the participant should be able to:

• 1. Analyze the new data and research available from respected institutions.
• 2. Assess new therapies available to treat patients and know how to incorporate these therapies into practice.
• 3. Evaluate new drug therapies including the mechanism of action (MOA).
• 4. Identify barriers that may prevent healthcare professionals from implementing new therapies into their practice and understanding steps they can take to address these barriers.
• 5. Modify current practice to improve patient outcomes by incorporating the most current therapies for hematologic malignancies to increase equitable optimal management of treatment plans and care to patients to minimize risk and adverse effects (e.g., toxicity) and improve patient outcomes, survival and quality of life.
• 6. Evaluate the best treatment options for AML patients where transplantation is not an option.
• 7. Identify the emerging and targeted therapies for the treatment of Relapsed and Refractory AML and describe how to put these treatment options into practice.
• 8. Identify the emerging treatment options for Myelodysplastic Syndromes and describe how to put these treatment options into practice.
• 9. Discuss treatment options for managing patients with Chronic Myeloid Leukemia in the current landscape.
• 10. Identify the new treatment options for Multiple Myeloma and describe how to put these treatment options into practice.
• 11. Describe management of adverse reactions to Multiple Myeloma therapy.
• 12. Review the emerging treatment options for Relapsed / Refractory Multiple Myeloma and describe how to put these treatment options into practice.
• 13. Evaluate the most current and treatment options for Waldenstrom’s Macroglobulinemia.
• 14. Assess and adjust diagnostic and treatment strategies for patients with Amyloidosis to include latest options.
• 15. Describe the current landscape surrounding treatment recommendations for patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia.
• 16. Identify the most effective therapies needed to manage bleeding and clotting disorders such as Sickle Cell Disease.
• 17. Evaluate the diagnosis for Myeloproliferative Neoplasms including how best to treat this disease.
• 18. Improve the management of patients with Myelofibrosis, Philadelphia Chromosome Negative Myeloproliferative Neoplasms and Systemic Mastocytocsis in their practice.
• 19. Identify the emerging treatment options for Acute Lymphoblastic Leukemia and describe how to put these treatment options into practice.
• 20. Explain how to effectively implement new Immune Effector Cell therapies for Lymphoid Malignancies in a community practice.
• 21. Evaluate the diagnosis for cellular blood disorders including how best to treat Initial and Relapsed Chronic Lymphocytic Leukemia.
• 22. Explain when it is important to “watch and wait” vs. treating patients with Indolent Lymphoma and Mantle Cell Lymphoma.
• 23. Adjust diagnostic and treatment strategies for patients with Hodgkin’s Lymphoma to include latest options.
• 24. Identify the emerging treatment options for Aggressive B and T Cell Lymphomas and describe how to put these treatment options into practice.
• 25. Explain how to effectively implement new Immune Effector Cell therapies for Multiple Myeloma in a community practice.
• 26. Discuss when it is important to refer vs. treat patients who have had Hematopoietic Transplantation and are on Cellular therapies.

ACCREDITATION

Physician Accreditation Statement

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Purdue University College of Pharmacy designates this live activity (Symposium 7:30 am - 7:00 pm) for a maximum of 9.75 AMA PRA Category 1 Credit(s)™. Purdue University College of Pharmacy designates this live activity (Town Hall Interactive Meeting 7:30 pm - 8:30 pm) for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 For more information please visit the official event page.